Se prevé que el mercado del tratamiento de la hematuria alcance los 1.103,61 millones de dólares en 2028, desde los 932,89 millones de dólares de 2021; se espera que crezca a una tasa compuesta anual del 2,4 % de 2021 a 2028.
La hematuria es una afección médica indicada por la presencia de sangre en la orina; En circunstancias normales, la orina no contiene glóbulos rojos. Esto puede provocar problemas graves que también pueden provocar cálculos renales, infecciones del tracto urinario y otras enfermedades hereditarias. Factores como la alta prevalencia de indicaciones asociadas a hematuria y la creciente conciencia sobre las opciones de tratamiento y la mejora del gasto sanitario están impulsando el mercado. Sin embargo, los casos no diagnosticados de indicaciones asociadas que obstaculizan la eficacia del tratamiento obstaculizan el crecimiento del mercado del tratamiento de la hematuria. Además, se espera que un mayor alcance para tratamientos relacionados ofrezca importantes oportunidades de crecimiento a los actores del mercado de Tratamiento de hematuria para ampliar su base de clientes, especialmente en los países en desarrollo.Perspectivas estratégicas
< p>Europa fue testigo de un crecimiento exponencial en el número de casos de COVID-19 en 2020. España, Alemania, Francia, Italia y el Reino Unido son los países más afectados de la región. Se informa que la proteinuria y la hematuria tienen una mayor prevalencia entre los pacientes con COVID-19 que en los pacientes con IRA. Estudios retrospectivos en China han informado que se observan proteinuria y hematuria en pacientes con COVID-19, y las condiciones también se asocian con una mayor mortalidad. Según la base de datos COVID-19 de la Asociación Europea del Riñón (ERACODA), establecida en marzo de 2020, ~25 % de los pacientes con trasplante de riñón son diagnosticados con SARS-CoV-2. Por lo tanto, los pacientes con COVID-positivo tienen más probabilidades de recibir también tratamientos contra las enfermedades renales.regiones lucrativas para el mercado de tratamiento de hematuria
< h3>Perspectivas del mercadoLa alta prevalencia de indicaciones asociadas a la hematuria impulsa el crecimiento del mercado del tratamiento de la hematuria
La enfermedad renal crónica (ERC) es una afección común y potencialmente mortal que afecta a una mayor población en todo el mundo . Existen varios tipos de ERC, como cálculos renales, glomerulonefritis, poliquistosis renal e infecciones del tracto urinario. La ERC es una de las causas clave detrás de la prevalencia de la hematuria. Por ejemplo, según un estudio publicado en el Centro Nacional de Información Biotecnológica en mayo de 2019, las infecciones del tracto urinario (ITU) generalmente se observan como infecciones ambulatorias en los EE. UU. y ocurren principalmente entre mujeres del grupo de edad de entre 14 y 24 años. Además, la prevalencia de ITU entre mujeres mayores de 65 años es aproximadamente del 20% en comparación con la población general, que es aproximadamente del 11%. Actualmente, el mercado mundial del tratamiento de la hematuria se está beneficiando significativamente de la creciente prevalencia de indicaciones asociadas. En América del Norte, Estados Unidos es el mercado más grande para el tratamiento de la hematuria. El crecimiento de este mercado está impulsado principalmente por la creciente prevalencia de trastornos renales crónicos (ERC) y el creciente número de lanzamientos de productos por parte de actores clave. Por ejemplo, en 2016, los Centros para el Control y la Prevención de Enfermedades (CDC) declararon que se estimaba que 0,7 millones de personas recibieron tratamiento por enfermedad renal terminal (ESRD) en los EE. UU. La prevalencia de ESRD se duplicó con creces entre 1990 y 2016. Además , el aumento de la incidencia de hematuria entre los adultos, el aumento de la concienciación, la investigación exhaustiva y la investigación. También se espera que las actividades de desarrollo impulsen la prevalencia de los tratamientos de hematuria, lo que eventualmente ofrecerá una oportunidad lucrativa para el crecimiento del mercado. El aumento de la población geriátrica también es uno de los principales impulsores de este mercado, ya que el envejecimiento es el principal factor de riesgo responsable de la creciente incidencia de enfermedades renales. Por ejemplo, según un estudio publicado por el Population Reference Bureau en 2020, se espera que la población de 65 años en EE. UU. se duplique para 2060.
Tratamiento basado en Insights
El mercado del tratamiento de la hematuria, basado en el tratamiento, se segmenta en medicamentos, terapias y otros. Como la hematuria se asocia con diversas indicaciones, como infección urinaria, cálculos renales, cáncer de sangre, cálculos en la vejiga y cáncer de próstata, los medicamentos utilizados para estas indicaciones también se pueden utilizar para su tratamiento. La alfuzosina, la ciprofloxacina, la doxazosina, el ibuprofeno y la tamsulosina se encuentran entre los fármacos más utilizados para el tratamiento de la hematuria. Este es un tipo de tratamiento preferido ya que los medicamentos se pueden administrar en casa y en entornos sanitarios.
Mercado de tratamiento de hematuria, por tratamiento: 2020 y 2028
Perspectivas basadas en indicaciones
El mercado del tratamiento de la hematuria, según la indicación , se segmenta en cálculos renales, infecciones del tracto urinario (ITU), uretritis, cáncer de sangre, cálculos en la vejiga, cáncer de próstata, cistitis, traumatismos, ejercicio vigoroso, poliquistosis renal, endometriosis y menstruación. En 2021, es probable que el segmento de infecciones del tracto urinario tenga la mayor participación del mercado. Además, también se espera que el mercado de tratamiento de hematuria para el segmento de uretritis registre la CAGR más rápida del 3,1% durante 2021 a 2028.
Información basada en tipos
El mercado del tratamiento de la hematuria, según el tipo, se ha segmentado en hematuria macroscópica, hematuria microscópica, hematuria idiopática y hematuria del corredor. Es probable que el segmento de hematuria macroscópica tenga la mayor participación del mercado en 2021. Sin embargo, se prevé que el segmento de hematuria microscópica registre la CAGR más alta del mercado durante el período de pronóstico.
Información basada en el usuario final
El mercado del tratamiento de la hematuria, según el usuario final, está segmentado en hospitales, clínicas, centros quirúrgicos ambulatorios (ASC) y otros. En 2021, se espera que el segmento de hospitales tenga la mayor participación del mercado. Además, también se espera que el segmento de clínicas experimente un crecimiento en su demanda a la CAGR más rápida del 6,9% durante 2021 a 2028.
Las empresas que operan en el mercado de tratamiento de hematuria adoptan la estrategia de innovación en tratamientos para satisfacer las cambiantes demandas de los clientes en todo el mundo, lo que también les permite mantener su marca en el mercado global.
Mercado de tratamiento de hematuria: ndash; por Tratamiento
- Fármacos
- Terapias
- Otros
Mercado de tratamiento de hematuria: por indicación
- Infecciones del tracto urinario
- Cálculos renales
- Uretritis
- Cáncer de sangre
- Cálculos en la vejiga
- Próstata Cáncer
- Cistitis, Trauma
- Ejercicio vigoroso
- Riñón poliquístico Enfermedad
- Endometriosis
- Menstruación
Mercado de tratamiento de hematuria - ndash; por tipo
- Hematuria macroscópica
- Hematuria microscópica
- Hematuria idiopática
- Hematuria de Jogger
Mercado de tratamiento de hematuria - ndash; por usuario final
- Hospitales
- Clínicas
- ASC
- Otros
Mercado de tratamiento de hematuria– por Geografía
- América del Norte
- Estados Unidos
- Canadá
- México
< li>Europa - Francia
- Alemania
- Italia
- Reino Unido
- España
- Resto de Europa
- Asia Pacífico (APAC)
- China
- India
- Corea del Sur
- Japón
- Australia
- Resto de APAC
- Oriente Medio y África (MEA)
- Sudáfrica
- Arabia Saudita
- EAU
- Resto de MEA
- América del Sur y Central (SCAM )
- Brasil
- Argentina
- Resto de ESTAFA
Perfiles de empresas
- AstraZeneca
- Compañía Bristol-Myers Squibb
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Hematuria is the presence of blood in the urine. Gross or visible hematuria occurs when the urine is red or pink, indicating the presence of blood in the urine. Blood can sometimes be found in the urine but is difficult to see; this is known as microscopic hematuria since it can only be seen under a microscope. The need for hematuria treatment has increased as the incidence of chronic renal disease and urinary tract infections has increased. Many tests, such as screening for sugar (diabetes), germs (infection), and blood, are performed on a regular basis. Blood can be detected with a chemical strip (also known as a dipstick) or under a microscope.
Key factors that are driving the growth of this market are high prevalence of hematuria-associated indications and increasing awareness about treatment options and improving healthcare expenditure are expected to boost the market growth for the hematuria treatments over the years.
The CAGR value of the hematuria treatments market during the forecasted period of 2021-2028 is 2.4%.
The drugs segment held the largest share of the market in the global hematuria treatments market and held the largest market share of 56.99% in 2020.
The urinary tract infections segment dominated the global hematuria treatments market and accounted for the largest market share of 17.31% in 2020.
The macroscopic hematuria segment dominated the global hematuria treatments market and held the largest market share of 48.04% in 2020.
The hospitals segment dominated the global hematuria treatments market and held the largest market share of 36.52% in 2020.
The hematuria treatments market majorly consists of the players such AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH among others.
The List of Companies - Hematuria Treatment Market
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Oct 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Oct 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Oct 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Oct 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Oct 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)